ABBV

AI Research

ABBV-295 obesity pipeline advance + Humira cliff navigated → $247 avg PT

AbbVie is experiencing positive momentum with promising Phase 2 clinical data for its obesity treatment ABBV-295 and advancing its risankizumab dosing study for immunology indications. The company has effectively managed the Humira biosimilar patent cliff through strong growth in Skyrizi and Rinvoq, entering 2026 with a diversified portfolio. Trading near $221, the stock has a consensus Buy rating from 19 analysts with a 12-month average price target of $247.06, representing 11.3% upside; the key risk remains pipeline execution and competitive pricing pressure.